CWRU and UTMC-linked Rodeo Therapeutics is set to be acquired by Amgen for $55m in upfront and up to $666m in milestone payments.
Rodeo Therapeutics, a US-based small-molecule therapy developer based on research at Case Western Reserve University and University of Texas Southwestern Medical Center, has agreed to an acquisition by pharmaceutical firm Amgen for up to $721m.
Amgen will pay an initial $55m and up to $666m in cash subject to milestones.
Rodeo is developing small-molecule therapies, including its lead 15-prostaglandin dehydrogenase (15-PGDH) modulators, that will help regenerate and repair various types of tissue, for use in dealing with conditions such as…
